Abstract | INTRODUCTION: Whole-body x-ray (WBX) is used for detecting skeleton abnormalities in patients with multiple myeloma (MM). An alternative might be 18F-FDG PET, which makes use of metabolic changes of malignant cells. The aims of this study were to evaluate whether 18F-FDG PET detects more lesions compared with WBX in patients with relapsing MM and to define its prognostic value. In addition 1-α-D-(5-deoxy-5-[F]-fluoroarabinofuranosyl)-2- nitroimidazole (18F-FAZA) scan and immunohistochemical staining on bone marrow were performed to define whether FDG uptake coincides with angiogenesis-related tumor hypoxia. PATIENTS AND METHODS: RESULTS: New lesions were more frequently demonstrated on 18F-FDG PET than on WBX (P = 0.000001). 18F-FDG PET was not predictive for progression-free survival and overall survival. Immunohistochemical staining on bone marrow biopsies demonstrated a significant increase in microvessel density and elevated expression of vascular endothelial growth factor, HIF-2α, and glucose transport protein 3 by the malignant plasma cells. However, HIF-1α expression and 18F-FAZA scan results were negative. CONCLUSIONS: Our results demonstrate that 18F-FDG PET is relevant for diagnostic purposes compared with WBX in relapsing MM. The enhanced uptake of 18F-FDG PET is likely related to the activation of the HIF-2α signaling pathway but probably independent of hypoxia-induced signaling in view of the negative findings on both 18F-FAZA-PET and HIF-1α expression.
|
Authors | Esther G M de Waal, Riemer H J A Slart, Marnix J Leene, Philip M Kluin, Edo Vellenga |
Journal | Clinical nuclear medicine
(Clin Nucl Med)
Vol. 40
Issue 4
Pg. 291-6
(Apr 2015)
ISSN: 1536-0229 [Electronic] United States |
PMID | 25546223
(Publication Type: Evaluation Study, Journal Article)
|
Chemical References |
- Basic Helix-Loop-Helix Transcription Factors
- Glucose Transporter Type 1
- Glucose Transporter Type 3
- HIF1A protein, human
- Hypoxia-Inducible Factor 1, alpha Subunit
- Nitroimidazoles
- Radiopharmaceuticals
- SLC2A1 protein, human
- SLC2A3 protein, human
- Vascular Endothelial Growth Factor A
- Fluorodeoxyglucose F18
- endothelial PAS domain-containing protein 1
- fluoroazomycin arabinoside
|
Topics |
- Basic Helix-Loop-Helix Transcription Factors
(metabolism)
- Bone Marrow
(metabolism, pathology)
- Bone Neoplasms
(diagnostic imaging, metabolism, secondary)
- Cell Hypoxia
- Female
- Fluorodeoxyglucose F18
- Glucose Transporter Type 1
(metabolism)
- Glucose Transporter Type 3
(metabolism)
- Humans
- Hypoxia-Inducible Factor 1, alpha Subunit
(metabolism)
- Male
- Middle Aged
- Multiple Myeloma
(diagnostic imaging, metabolism, pathology)
- Nitroimidazoles
- Positron-Emission Tomography
- Radiopharmaceuticals
- Vascular Endothelial Growth Factor A
(metabolism)
|